Actively Recruiting
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
Led by Zhou Chengzhi · Updated on 2026-02-04
60
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of precise and effective diagnostic techniques often leads to underdiagnosis and misdiagnosis. The investigators conducted a prospective clinical study to evaluate the effectiveness of ¹H-nuclear magnetic resonance (NMR)-based lipoprotein and metabolite analysis in diagnosing checkpoint inhibitor-related pneumonitis (CIP), aiming to improve its early diagnosis rate.
CONDITIONS
Official Title
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a pathological diagnosis of lung cancer
- Have received at least one course of immune checkpoint inhibitor treatment
- Able to understand and voluntarily sign an informed consent form
- For CIP group: suspected checkpoint inhibitor pneumonitis based on lung symptoms or radiological abnormalities
- For Control group: no clinical symptoms or radiographic evidence of pneumonitis at or before enrollment
You will not qualify if you...
- Pulmonary lesions diagnosed as tumor progression, bacterial pneumonia, or pulmonary edema
- Incomplete or missing follow-up data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510100
Actively Recruiting
Research Team
C
Chengzhi Zhou, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here